title: Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer.
abstract: OBJECTIVE
  Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy. To stage the cancer, choline positron emission tomography (PET)/CT can be performed. It is generally thought that androgen deprivation therapy does not influence choline PET/CT. In this article we focus on the molecular backgrounds of choline and androgens, and the results of preclinical and clinical studies performed using PET/CT.
  
  
  METHODS
  Using PubMed, we looked for the relevant articles about androgen deprivation therapy and choline PET/CT.
  
  
  RESULTS
  During ADT, a tendency of decreased uptake of choline in prostate cancer was observed, in particular in hormone-naïve patients.
  
  
  CONCLUSIONS
  We conclude that in order to prevent false-negative choline PET/CT scans androgen deprivation should be withheld prior to scanning, especially in hormone-naïve patients.
authors.affiliation: Department of Urology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. rj.dost@umcg.nl
authors.forename: Rutger J
authors.initials: RJ
authors.lastname: Dost
authors.forename: Andor W J M
authors.initials: AW
authors.lastname: Glaudemans
authors.forename: Anthonius J
authors.initials: AJ
authors.lastname: Breeuwsma
authors.forename: Igle J
authors.initials: IJ
authors.lastname: de Jong
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000728:Androgens / Q000172:deficiency* / Q000378:metabolism; D002794:Choline / Q000378:metabolism; D006801:Humans; D008297:Male; D064847:Multimodal Imaging; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism; D019275:Radiopharmaceuticals / Q000378:metabolism; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D019275:Radiopharmaceuticals; D002794:Choline
references.citation: J Biol Chem. 1956 Sep;222(1):193-214
references.pmid: 13366993
references.citation: Clin Cancer Res. 2012 Jun 15;18(12):3261-9
references.pmid: 22510345
references.citation: Prostate Cancer Prostatic Dis. 2012 Mar;15(1):45-55
references.pmid: 21844889
references.citation: Clin Cancer Res. 2011 Jun 1;17(11):3751-9
references.pmid: 21493868
references.citation: Magn Reson Med. 2001 Jul;46(1):49-57
references.pmid: 11443710
references.citation: Prog Lipid Res. 2004 May;43(3):266-81
references.pmid: 15003397
references.citation: Mol Imaging. 2008 May-Jun;7(3):147-52
references.pmid: 19123985
references.citation: Eur Urol. 2010 Jan;57(1):49-59
references.pmid: 19683858
references.citation: N Engl J Med. 2009 Jun 11;360(24):2516-27
references.pmid: 19516032
references.citation: Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1842-53
references.pmid: 21732108
references.citation: Urol Clin North Am. 1975 Feb;2(1):125-40
references.pmid: 48206
references.citation: BJU Int. 2006 Feb;97(2):247-54
references.pmid: 16430622
references.citation: Cancer Res. 2010 Sep 1;70(17):6692-6
references.pmid: 20699363
references.citation: Cancer Treat Rev. 2009 Nov;35(7):540-6
references.pmid: 19493624
references.citation: Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1065-73
references.pmid: 18200444
references.citation: Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):9-17
references.pmid: 17828534
references.citation: Mol Imaging Biol. 2006 Jan-Feb;8(1):43-8
references.pmid: 16315004
references.citation: Cancer Res. 2001 Jan 1;61(1):110-7
references.pmid: 11196147
references.citation: Biochem Biophys Res Commun. 2002 Aug 23;296(3):580-3
references.pmid: 12176020
references.citation: Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019
references.pmid: 17054269
references.citation: Biochem J. 2002 May 1;363(Pt 3):777-84
references.pmid: 11964179
references.citation: Nucl Med Commun. 2012 Aug;33(8):889-94
references.pmid: 22692582
references.citation: Cancer Treat Rev. 2009 Feb;35(1):9-17
references.pmid: 18926640
references.citation: Arterioscler Thromb Vasc Biol. 1996 Apr;16(4):591-9
references.pmid: 8624782
references.citation: Oncogene. 2003 Dec 4;22(55):8803-12
references.pmid: 14654777
references.citation: Expert Opin Investig Drugs. 2001 Apr;10(4):709-20
references.pmid: 11281820
references.citation: Anticancer Res. 1996 May-Jun;16(3B):1375-80
references.pmid: 8694504
references.citation: Mol Imaging. 2006 Oct-Dec;5(4):498-509
references.pmid: 17150162
references.citation: Clin Nucl Med. 2010 Sep;35(9):701-3
references.pmid: 20706046
references.citation: PLoS One. 2009 Nov 12;4(11):e7819
references.pmid: 19915674
references.citation: Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):301-9
references.pmid: 19756592
references.citation: Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1985-9
references.pmid: 21732105
references.citation: Eur J Nucl Med Mol Imaging. 2006 Dec;33(12):1387-98
references.pmid: 16865395
references.citation: Am J Pathol. 2011 Feb;178(2):525-36
references.pmid: 21281786
references.citation: Oncogene. 1997 Nov 6;15(19):2289-301
references.pmid: 9393874
references.citation: Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):18-23
references.pmid: 17891394
references.citation: Nucl Med Biol. 2006 Nov;33(8):977-84
references.pmid: 17127170
references.citation: J Urol. 2002 Jul;168(1):273-80
references.pmid: 12050555
references.citation: Mol Imaging Biol. 2009 Nov-Dec;11(6):446-54
references.pmid: 19326171
references.citation: Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):253-63
references.pmid: 17926036
references.citation: J Lipid Res. 2008 Jun;49(6):1187-94
references.pmid: 18204095
references.citation: BJU Int. 2007 Oct;100(4):786-93
references.pmid: 17822459
references.citation: J Clin Pathol. 2003 May;56(5):336-40
references.pmid: 12719451